Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372088 | 1.00 | NR1H2 (0.57) | NR1H2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL16192303 | 1.00 | NR1H2 (0.57) | NR1H2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL19597436 | 1.00 | NR1H2 (0.57) | NR1H2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL1425970 | 1.00 | NR1H2 (0.57) | NR1H2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL11957185 | 1.00 | NR1H2 (0.57) | NR1H2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL20567011 | 1.00 | NR1H2 (0.57) | NR1H2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL15273205 | 0.92 | NR1H2 (0.52) | NR1H2GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12324583 | 0.90 | JAK2 (0.49) | NR1H2GPR119JAK1JAK2HPGD | |
| SCHEMBL10321555 | 0.90 | JAK2 (0.49) | NR1H2GPR119JAK1JAK2HPGD | |
| SCHEMBL10449501 | 0.90 | JAK2 (0.49) | NR1H2GPR119JAK1JAK2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2022-06-16 | — | — | US | disclosed |
| WO-2022117075-A1 | AZACYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广州费米子科技有限责任公司 | 2022-06-09 | — | — | WO | disclosed |
| EP-3939979-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-01-19 | — | — | EP | disclosed |
| US-20140336207-A1 | PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREOF, AND MEDICINAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-11-13 | — | — | US | disclosed |
| EP-2796460-A1 | PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICINAL USES THEREOF | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2014-10-29 | — | — | EP | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| WO-2012041158-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011113293-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 (CN) | 2011-09-22 | — | — | WO | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | NR1H2 355/4885GPR119 308/4885CHRM2 3698/4885 |
| US-20140336207-A1 | PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREOF, AND MEDICINAL USES THEREOF | JAK1, JAK3, JAK2 | NR1H2 3663/4885GPR119 4242/4885CHRM2 4857/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | NR1H2 979/4885GPR119 192/4885CHRM2 2774/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | NR1H2 423/4885GPR119 353/4885CHRM2 3978/4885 |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | JAK1, JAK2, JAK3 | NR1H2 3748/4885GPR119 2934/4885CHRM2 4797/4885 |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | PLK2, PLK3, DMPK | NR1H2 1812/4885GPR119 1668/4885CHRM2 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.